COMPANY

AVM Biotechnology, Inc.

HQ: Seattle, WA source · avmbiotech.com ↗ · West Coast

Keywords: oncology immunology cancer autoimmune diseases non-hodgkin's lymphoma leukemia Lymphoid Malignancies Glioblastoma Squamous Cell Carcinoma Hodgkin Lymphoma Non-hodgkin Lymphoma Breast Cancer Prostate Cancer Gastric Cancer Ovarian Cancer Acute Leukemia Pancreatic Cancer Spindle Cell Sarcoma Brain Tumor Esophageal Andeocarcinoma Mixed Phenotype AML Desmoplastic Round Cell Sarcoma ARDS Covid19 Human Influenza AVM0703

Location: Seattle, WA · source · May 3, 2021

Profile checked Oct 10, 2026

3Trials (company is sponsor)7NIH grants

Timeline

Dec 1, 2026 Trial start Phase 1: Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS source ↗
Sep 8, 2025 Grant Government grant — SBIR: $992,425 (annual award, as published), announced Sep 8, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Nov 6, 2020 Trial start Phase 1/Phase 2: The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies source ↗

Upcoming milestones

Nov 30, 2027 (ESTIMATED) · Phase 1/Phase 2 · The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies · NCT04329728
Dec 1, 2031 (ESTIMATED) · Phase 1 · Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS · NCT04366115

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Sep 8, 2025 Government grant — SBIR: $992,425 (annual award, as published), announced Sep 8, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT04329728	The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies	Phase 1/Phase 2	Recruiting	Nov 6, 2020	Nov 30, 2027 (estimated)
NCT05974410	Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients	Not listed	Available	Not listed	Not listed
NCT04366115	Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS	Phase 1	Not yet recruiting	Dec 1, 2026	Dec 1, 2031 (estimated)

NIH awards 7

Annual award amounts. Total $4.5M.

May 10, 2023 NIH award 5R44CA272096-02 FY2023: $999,999 awarded for that fiscal year; activity R44 (SBIR); PI DEISHER, THERESA A; recipient as written: AVM BIOTECHNOLOGY, LLC, SEATTLE, WA. Expedited Expansion Cohort Clinical Tria source ↗
Mar 30, 2023 NIH award 5R44DK121634-03 FY2023: $963,581 awarded for that fiscal year; activity R44 (SBIR); PI DEISHER, THERESA A; recipient as written: AVM BIOTECHNOLOGY, LLC, SEATTLE, WA. Targeted Lymphoablation as an alternativ source ↗
Aug 5, 2022 NIH award 1R43CA271951-01A1 FY2022: $399,193 awarded for that fiscal year; activity R43 (SBIR); PI DEISHER, THERESA A; recipient as written: AVM BIOTECHNOLOGY, LLC, SEATTLE, WA. AVM0703 combined with Non-Hodgkin's Ly source ↗
Jun 10, 2022 NIH award 1R44CA272096-01 FY2022: $999,999 awarded for that fiscal year; activity R44 (SBIR); PI DEISHER, THERESA A; recipient as written: AVM BIOTECHNOLOGY, LLC, SEATTLE, WA. Expedited Expansion Cohort Clinical Tria source ↗
Mar 30, 2022 NIH award 2R44DK121634-02A1 FY2022: $667,733 awarded for that fiscal year; activity R44 (SBIR); PI DEISHER, THERESA A; recipient as written: AVM BIOTECHNOLOGY, LLC, SEATTLE, WA. Targeted Lymphoablation as an alternat source ↗
May 29, 2020 NIH award 1R43CA246896-01A1 FY2020: $224,770 awarded for that fiscal year; activity R43 (SBIR); PI DEISHER, THERESA A; recipient as written: AVM BIOTECHNOLOGY, LLC, SEATTLE, WA. A novel non-toxic preconditioning regi source ↗
Sep 19, 2019 NIH award 1R43DK121634-01A1 FY2019: $211,047 awarded for that fiscal year; activity R43 (SBIR); PI DEISHER, THERESA A; recipient as written: AVM BIOTECHNOLOGY, LLC, SEATTLE, WA. Targeted lympho-ablation as an alterna source ↗